X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Orchid Chemicals with TEVA PHARMACEUTICAL INDUSTRIES LTD. - Israel - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA LTD vs TEVA PHARMA (Israel) - Comparison Results

ORCHID PHARMA LTD    Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

TEVA PHARMA (Israel)
   Change

Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 ORCHID PHARMA LTD   TEVA PHARMA
EQUITY SHARE DATA
    ORCHID PHARMA LTD
Sep-13
TEVA PHARMA
Dec-13
ORCHID PHARMA LTD/
TEVA PHARMA
5-Yr Chart
Click to enlarge
High Rs1943,075-   
Low Rs352,672-   
Sales per share (Unadj.) Rs276.51,765.0-  
Earnings per share (Unadj.) Rs-79.2110.3-  
Cash flow per share (Unadj.) Rs-43.5252.9-  
Dividends per share (Unadj.) Rs096.52-  
Dividend yield (eoy) %03.4 0.0%  
Book value per share (Unadj.) Rs53.91,960.6-  
Shares outstanding (eoy) m70.45848.00-   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x0.41.6 25.4%   
Avg P/E ratio x-1.426.1 -5.5%  
P/CF ratio (eoy) x-2.611.4 -23.2%  
Price / Book Value ratio x2.11.5 144.8%  
Dividend payout %087.5 0.0%   
Avg Mkt Cap Rs m8,0672,436,745 0.3%   
No. of employees `0002.844.9 6.2%   
Total wages/salary Rs m2,5270-   
Avg. sales/employee Rs Th6,956.133,301.5 20.9%   
Avg. wages/employee Rs Th902.50-   
Avg. net profit/employee Rs Th-1,993.02,080.3 -95.8%   
INCOME DATA
Net Sales Rs m19,4771,496,736 1.3%  
Other income Rs m4070-   
Total revenues Rs m19,8841,496,736 1.3%   
Gross profit Rs m1,103409,882 0.3%  
Depreciation Rs m2,519120,983 2.1%   
Interest Rs m5,22729,398 17.8%   
Profit before tax Rs m-6,236259,501 -2.4%   
Minority Interest Rs m201,179 1.7%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m511-170,348 -0.3%   
Tax Rs m-125-3,168 4.0%   
Profit after tax Rs m-5,58093,500 -6.0%  
Gross profit margin %5.727.4 20.7%  
Effective tax rate %2.0-1.2 -164.4%   
Net profit margin %-28.76.2 -458.6%  
BALANCE SHEET DATA
Current assets Rs m11,0141,010,890 1.1%   
Current liabilities Rs m32,060881,581 3.6%   
Net working cap to sales %-108.18.6 -1,250.7%  
Current ratio x0.31.1 30.0%  
Inventory Days Days9591 104.5%  
Debtors Days Days3496 35.0%  
Net fixed assets Rs m29,440488,867 6.0%   
Share capital Rs m7053,684 19.1%   
"Free" reserves Rs m2,0430-   
Net worth Rs m3,8001,662,589 0.2%   
Long term debt Rs m9,018765,314 1.2%   
Total assets Rs m46,5103,420,520 1.4%  
Interest coverage x-0.29.8 -2.0%   
Debt to equity ratio x2.40.5 515.6%  
Sales to assets ratio x0.40.4 95.7%   
Return on assets %-0.83.6 -21.2%  
Return on equity %-146.95.6 -2,611.3%  
Return on capital %-3.74.9 -75.7%  
Exports to sales %37.90-   
Imports to sales %22.60-   
Net fx Rs m1,8650-   
CASH FLOW
From Operations Rs m1,682238,502 0.7%  
From Investments Rs m-9,860-84,511 11.7%  
From Financial Activity Rs m6,644-286,099 -2.3%  
Net Cashflow Rs m-1,535-132,108 1.2%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 73.68 Rs / USD

Compare ORCHID PHARMA LTD With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  

Compare ORCHID PHARMA LTD With: STRIDES SHASUN LTD  J.B.CHEMICALS  MERCK LTD  NATCO PHARMA  SUN PHARMA  



Today's Market

Sensex Ends 132 Points Higher; IT and Healthcare Stocks Witness Buying(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed buying interest during the closing hours and ended the day in green.

Related Views On News

ORCHID PHARMA LTD Announces Quarterly Results (4QFY18); Net Profit Up 50.8% (Quarterly Result Update)

Aug 24, 2018 | Updated on Aug 24, 2018

For the quarter ended March 2018, ORCHID PHARMA LTD has posted a net profit of Rs 924 m (up 50.8% YoY). Sales on the other hand came in at Rs 2 bn (down 24.0% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

Eris Lifesciences Limited (IPO)

Jun 15, 2017

Exposure to high margin specialty products offers promising growth prospects.

More Views on News

Most Popular

Don't Panic in This Falling Market... Do This Instead(The 5 Minute Wrapup)

Oct 5, 2018

Find companies with long term durable moats, which are correcting with the current broader market sell-off.

Why You Should Be Excited, Not Sad, About the 30% Small Cap Crash(Profit Hunter)

Oct 4, 2018

Smallcaps have corrected over 30% since the beginning of the year. Find out why Richa Agarwal views this as an opportunity rather than a threat.

Taxpayers to pay salaries of CEOs/CIOs of Mutual Funds(The Honest Truth)

Oct 5, 2018

Ajit Dayal on the crisis in the market and in the mutual fund industry.

Why Are Investors In Sundaram Small Cap Fund Anxious(Outside View)

Oct 3, 2018

A small cap fund that aims to capitalise on emerging businesses and catch them young. However, its failure in keeping volatility under check is making its investors anxious.

Biggest Corrections in the Stock of Infibeam Avenues(Chart Of The Day)

Oct 3, 2018

Infibeam plunged over 70% last week. This was the second biggest single-day fall. But Infibeam witnessed such sharp falls earlier.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA LTD SHARE PRICE


Oct 15, 2018 (Close)

TRACK ORCHID PHARMA LTD

  • Track your investment in ORCHID PHARMA LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ORCHID PHARMA LTD

ORCHID PHARMA LTD 5-YR ANALYSIS

COMPARE ORCHID PHARMA LTD WITH

MARKET STATS